GLP-1 Peptide Atlas, by Delfa

Completed

Semaglutide Use in Acute Pulmonary Embolism

Evaluation of Circulating Endothelial Inflammatory Biomarkers in Response to GLP-1 Agonist Semaglutide in Acute Pulmonary Embolism

Lead sponsor

Imperial College London

Assets

GLP-1 / incretin class catch-all / Semaglutide

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Cardiovascular disease

Key I/E criterion

—

Primary endpoint

•Endothelial biomarker measurement

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06118203

Org study ID300440

Timeline

Milestones

Study start2022-01-02actual

Primary completion2023-03-04actual

Study completion2023-03-05actual

Study first posted2023-11-07actual

Last update posted2026-03-27actual

Assets

Investigational agents

GLP-1 / incretin class catch-all Semaglutide

Study populations

Who this study enrolls

Cardiovascular disease

Eligibility

Who can enroll

Minimum age18 Years

Maximum age80 Years

SexAll

Healthy volunteersNot accepted

Sampling methodNon probability sample

Study population text

Acute admission with acute pulmonary embolism

Inclusion criteria

Acute pulmonary embolism

Exclusion criteria

Concurrent use of GLP-1 agonist

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

2 endpoints

Primary/protocol endpoint/low confidence

Endothelial biomarker measurement

Time frame:4 weeks

change from baseline, improvement

Secondary/protocol endpoint

Plasma proteomics

Time frame:4 weeks

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

GLP-1 agonist, semaglutide use in acute pulmonary embolism recovery: a four-week proof-of-concept study including proteomic profiling.
European heart journal open2026 Jan (month)PMID41536961doi:10.1093/ehjopen/oeaf170via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.